Sunnova Energy International Inc.

    Sunnova Energy International Inc.

    NNYSE:NOVA
    - -
    USD
    - -
    - -
    Sunnova Energy International Inc.
    NYSE:NOVA
    (New York Stock Exchange)

    Recent

    price

    - -

    P/E

    ratio

    - -

    div

    yld

    - -

    ROIC.AI

    2017
    2018
    2019
    2020
    2021
    2022
    2023
    2024
    TTM
    USD
    0.92
    1.26
    3.22
    1.83
    2.18
    4.87
    6.09
    6.76
    6.77
    Revenue per Share
    -1.46
    -1.63
    -4.14
    -2.87
    -1.25
    -1.41
    -3.53
    -2.96
    -2.97
    Basic EPS, GAAP
    -3.48
    -3.18
    -14.73
    -8.08
    -6.89
    -10.5
    -17.49
    -15.73
    -15.76
    Free Cash Flow per Basic Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Dividend per Share
    -2.92
    -3.44
    -8.87
    -6.04
    -4.15
    -3.19
    -1.93
    0.38
    0.38
    Book Value per Share
    4.92
    7.05
    20.06
    14.57
    12.79
    14.96
    16.86
    20.77
    20.81
    Tangible Book Value per Share
    83
    83
    41
    88
    111
    114
    118
    124
    124
    Basic Weighted Avg Shares
    77
    104
    132
    161
    242
    558
    721
    840
    840
    Sales/Revenue/Turnover
    -13.47
    -13.15
    -16.93
    -22.25
    -22.71
    -14.61
    -31.96
    -21.99
    -21.99
    Operating Margin (%)
    29
    39
    49
    66
    107
    137
    182
    257
    257
    Depreciation Expense
    -91
    -74
    -144
    -252
    -138
    -162
    -418
    -368
    -368
    Net Income, GAAP
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Effective Tax Rate (%)
    -118.51
    -71.13
    -109.73
    -156.87
    -57.14
    -28.98
    -58
    -43.8
    -43.8
    Profit Margin (%)
    -73
    -6
    79
    246
    305
    406
    -159
    -296
    -296
    Working Capital
    724
    916
    1,346
    1,925
    3,136
    5,195
    7,031
    8,133
    8,133
    LT Debt
    410
    587
    818
    1,281
    1,622
    1,887
    2,129
    2,685
    2,685
    Total Equity
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)

    Capital Structure

    USD

    •

    in mil. unless spec.
    Jun'24
    Sep'24
    Dec'24
    ST Debt
    338
    330
    327
    LT Borrowings
    7,645
    7,909
    8,133
    LT Finance Leases
    - -
    - -
    - -
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    125
    125
    125
    Market Capitalization
    682
    1,208
    425

    Working Capital

    USD

    •

    in mil. unless spec.
    Jun'24
    Sep'24
    Dec'24
    Total Current Assets
    1,053
    915
    1,028
    Cash, Cash Equivalents & STI
    253
    209
    211
    Accounts Receivable, Net
    44
    46
    44
    Inventories
    132
    137
    127
    Total Current Liabilities
    1,088
    1,059
    1,324
    Payables & Accruals
    677
    659
    904
    ST Debt
    338
    330
    327
    Deferred Revenue
    55
    63
    60

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    - -
    27.69%
    26.13%
    Free Cash Flow
    - -
    29.94%
    -5.63%
    Net Income, GAAP
    - -
    38.63%
    -11.98%
    Sales/Revenue/Turnover
    - -
    49.8%
    16.55%
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    66
    147
    149
    196
    558
    2023
    162
    166
    198
    194
    721
    2024
    161
    220
    235
    224
    840

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    -0.31
    -0.36
    -0.56
    -0.25
    -1.41
    2023
    -0.7
    -0.74
    -0.53
    - -
    -3.53
    2024
    -0.57
    -0.27
    -0.98
    - -
    -2.96

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    - -
    - -
    - -
    - -
    - -
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • newsfilecorp.com

      EraNova Metals Files NI 43-101 Technical Report Supporting Updated Preliminary Economic Assessment for the Adanac Molybdenum Project

    • globenewswire.com

      LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia

    • globenewswire.com

      Haoxi Health Technology Limited Announces Strategic Cooperation Framework with NOVA MEDIA to Develop An AI Digital Marketing System

    • newsfilecorp.com

      EraNova Metals Advances 2026 Exploration Program at Ruby Creek

    • newsfilecorp.com

      Video - CEO Clips: EraNova Metals Advances Critical Mineral and Polymetallic Opportunities in British Columbia

    • newsfilecorp.com

      EraNova Metals Announces Closing of Oversubscribed Non-Brokered Private Placement

    • newsfilecorp.com

      EraNova to Participate in Upcoming Investor Conferences and Announces Investor Relations Agreements

    • newsfilecorp.com

      EraNova Metals Announces $600,000 Non-Brokered Private Placement

    • globenewswire.com

      LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia

    • newsfilecorp.com

      Toronto Stock Exchange, EraNova Metals Inc., The View from the C-Suite

    • newsfilecorp.com

      EraNova Metals to Participate at the John Tumazos Very Independent Research 2026 Virtual Conference

    • globenewswire.com

      LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102's Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)

    • globenewswire.com

      LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia

    • newsfilecorp.com

      EraNova Metals Identifies Rare Earth Element Potential at Adanac Through Re-Evaluation of Existing Assay Data; Announces Investor Relations Agreement; Announces Stock Option Grant

    • businesswire.com

      Dominion Energy, NOVA Parks reach new agreement for vegetation management in the Washington & Old Dominion Railroad Regional Park

    • newsfilecorp.com

      EraNova Metals Advances Adanac Molybdenum Project Toward PEA

    • businesswire.com

      Sunnova Receives Court Approval of Chapter 11 Plan

    • reuters.com

      Sunnova to sell part of solar panel business to Omnidian for $7 million

    • businesswire.com

      Sunnova Enters into Stalking Horse Asset Purchase Agreement with Omnidian

    • businesswire.com

      Sunnova Secures Interim Court Approval for Debtor-in-Possession Financing